| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Canton Strategic Holdings, Inc.$2.57
-0.14 (-4.93%)
D 31Pipeline Score NOT_PHARMA · Clinical
Market Cap
245.71 M
EPS
-2.00
P/E Ratio
-
Value Trade
1.61 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
267.82 K
Operating CF
-7.64 M
Total Assets
584.65 M
Total Liabilities
114.86 M
Equity
469.80 M
D/E Ratio
12,345
-2.22 %
Week
5.39 %
1 Month
-22.64 %
3 Month
57.14 %
6 Month
-99.75 %
5 Year
-99.75 %
All Time
Cash Data
Cash Position
41.53 M
Monthly Burn
2.54 M
Runway
14.6 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
774.39 K
52 Week Range
1.08 - 9.08
% held by Insiders
12.62 %
% held by Institutions
16.43 %
Enterprise Value
204.18 M
Total Shares
56.63 M
Short %
7.04 %
Float Shares
42.48 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Canton Strategic Holdings, Inc.
28Total events
0Upcoming
6Tier-1 (high impact)
2023 – 2026Coverage
Event history 28
Feb 18, 2026
●Quarterly UpdateCorporate
Corporate rebrand to Canton Strategic Holdings, Inc. and NASDAQ ticker change to CNTN
Feb 17, 2026
Jan 22, 2026
Jan 20, 2026
Jul 23, 2025
▼Equity OfferingCorporate
Pricing of $1.74 million registered direct public offering of common stock and warrants
Nov 2024
◆First Patient DosedTH104Trial
Expects to complete Phase 2 trial in chronic pruritis over approximately 12 months after aligning with FDA on trial design
chronic pruritis in PBCsource ↗
Nov 2024
◆Topline ReadoutTH104Clinical Data
Topline data from Phase 2 trial in chronic pruritis expected approximately 12 months after FDA alignment
chronic pruritis in PBCsource ↗
Sep 16, 2024
▲Partnership / LicenseINT-023Corporate
Tharimmune acquires global license from Intract Pharma for oral infliximab formulation
autoimmune diseasessource ↗
Drug Pipeline Intelligence
D31
Pipeline Score $16M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 37%
Micro Cap (rank 572 of 906)
Percentile RankCanton Strategic Holdings, Inc. faces pipeline headwinds (31/100), with $134M risk-adjusted pipeline value, led by Nalmefene in Pruritus (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nalmefene Small molecule | Pruritus | Phase 2 | NCT06733519 | 17% | $134M | NOT YET_RECRUITING | 40 | VERY_FAST | C (56) | Jun 1, 2027 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TH104 | chronic pruritus in primary biliary cholangitis (PBC) | Phase 1 | 2023-11-27 | Cmax: higher than the tablet product; AUC0: higher than the tablet product; safety: no deaths, other serious adverse events, or other significant adverse events reported Read More | Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic p Read More | |
TH104 | chronic pruritus in primary biliary cholangitis (PBC) | Phase 1 | 2023-11-27 | Cmax: higher than the tablet product; AUC0: higher than the tablet product; safety: no deaths, other serious adverse events, or other significant adverse events reported Read More | Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic p Read More | |
TH104 | chronic pruritus in primary biliary cholangitis (PBC) | Phase 1 | 2023-11-27 | Cmax: higher than the tablet product; AUC0: higher than the tablet product; safety: no deaths, other serious adverse events, or other significant adverse events reported Read More | Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic p Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CNTN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CNTN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CNTNCanton Strategic Holdings, Inc. Announces Authorization of Share Repurchase Program
Canton Strategic Holdings, Inc. has announced a $50 million share repurchase program, reflecting confidence in its platform's strength and long-term value for shareholders. The program allows the company to repurchase shares based on market conditions, share price, and other factors. This initiative is aligned with Canton Strategic's mission to enhance the institutional adoption of the Canton Network and its related technologies.
Read more →CNTNCanton Strategic Holdings Reports Full Year 2025 Financial and Operational Results First Annual Report Since Establishing Canton Network Digital Asset Strategy Highlights Accelerating Network Momentum and Strengthened Ca
Canton Strategic Holdings, Inc. reported its financial and operational results for the year ending December 31, 2025, marking the first annual report since establishing its digital asset strategy. The company highlighted a significant partnership with institutions and substantial holdings in Canton Coin, valued at over $501 million. However, it also faced challenges, including a net loss of $35.9 million and increased operating expenses amid the strategy's transition. Looking forward, the firm aims to enhance its capital base and implement disciplined expense management to bolster its growth in the evolving blockchain landscape.
Read more →CNTNCanton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board Appointment Underscores Canton Strategic Holdings' Leadership Role in Accelerating Institutional Adoption of the Canton Ne
Canton Strategic Holdings, Inc. announced the election of Chairman and CEO Mark Wendland to the Canton Foundation Board. This appointment signifies the company's leadership role in facilitating institutional adoption of the Canton Network, especially in the digitization of financial markets. The Canton Foundation oversees governance and operational standards within the network, making Wendland's membership pivotal for strengthening the network's credibility in the financial ecosystem.
Read more →CNTNCONFIDENTIAL DRAFT Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy New NASDAQ Ticker Symbol "CNTN" to Begin Trading
Tharimmune, Inc. has announced a corporate rebrand to Canton Strategic Holdings, Inc., effective February 18, 2026. This rebranding is part of their strategy to support institutional adoption of the Canton Network, which focuses on digital asset treasury initiatives. With this change, their stock will begin trading under the new ticker symbol 'CNTN'. Highlights of this announcement include securing Super Validator status and enhancing institutional expertise on their Board of Directors.
Read more →CNTNTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Le
Tharimmune, Inc. has appointed Mark Wendland as Chairman of the Board and Angela Radkowski as Chief Operating Officer, effective February 5, 2026. This leadership expansion aims to support the execution of the company's Canton Network strategy, which seeks to modernize financial market infrastructure using Canton Coin. Wendland and Radkowski bring significant industry experience and are expected to drive institutional adoption of the Canton Network, thereby enhancing shareholder value. The company focuses on bridging traditional financial markets with digital asset capabilities.
Read more →CNTNTharimmune Elects Jill Sommers and William Wiley to Board of Directors New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulat
Tharimmune, Inc. has elected Jill Sommers and William Wiley to its Board of Directors, effective February 1, 2026. Sommers, a former CFTC Commissioner, and Wiley, a seasoned capital markets expert, are expected to enhance the company's governance as it pursues its Canton Network strategy. Tharimmune aims to digitize traditional financial markets using Canton Coin and improve the financial infrastructure with their expertise. The additions reflect the company's commitment to compliance and modernization in the blockchain space.
Read more →CNTNTharimmune Announces Expanded Role as Super Validator on Canton Network Advances Digital Asset Treasury Strategy Through Contributions to Canton Network
Tharimmune, Inc. has announced its approval to function as a Super Validator on the Canton Network, enhancing its efforts in digitizing traditional financial markets. The role aims to secure transactions and generate rewards in Canton Coin, bolstering the company's digital asset treasury. CEO Mark Wendland highlighted the impact of the Canton Network on global financial infrastructure, while Tharimmune plans to support the adoption of institutional applications utilizing this technology. This collaboration positions Tharimmune as a key player in transforming financial markets through blockchain innovation.
Read more →CNTNTharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering
Tharimmune, Inc. has successfully closed a $55 million underwritten registered direct offering, issuing 1,800,000 shares at $2.92 each. The funds raised will be used to support the company's Canton-centric digital asset treasury strategy and provide working capital for corporate needs. This offering signifies Tharimmune's commitment to enhancing its growth potential in the blockchain and financial markets.
Read more →CNTNTharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
Tharimmune, Inc. has announced the pricing of an underwritten registered offering, raising $55 million through the issuance of 1,800,000 shares at $2.92 each. The capital is intended for the expansion of its digital asset treasury strategy leveraging the Canton Network and for general corporate purposes. The offering, which includes pre-funded warrants for additional shares, is expected to close on January 21, 2026, subject to customary conditions. This initiative marks a strategic step in advancing the company's blockchain-related financial operations.
Read more →CNTNTharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toom
Tharimmune, Inc. has appointed Jacob Asbury as its Chief Financial Officer, effective immediately. Asbury, who brings nearly two decades of financial leadership experience, will oversee financial strategy and operations to enhance the company's Canton Coin treasury strategy. His appointment reflects Tharimmune's commitment to innovating financial markets through the Canton Network. Asbury aims to create long-term value for shareholders and enhance the adoption of digital assets in institutional markets.
Read more →CNTNTharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy Led by DRW and Liberty City Ventures, Transaction Cements Tharimmune as First Public Company to Deliver Canton-Aligned DAT
Tharimmune, Inc. has successfully closed a $545 million private placement aimed at establishing a Canton Coin treasury strategy, becoming the first public company to engage with the Canton Network. The raised funds will be utilized to acquire the Canton Coin utility token and support the company's role as a Super Validator in the network. With leadership changes including a new CEO and President, Tharimmune aims to execute a differentiated digital asset strategy that promotes institutional adoption of blockchain technology. The private placement was backed by notable investors, highlighting confidence in Tharimmune's future.
Read more →CNTNTharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy Other Participants Include ARK Invest, Bitwave, Broadridge, Clear
Tharimmune, Inc. announced a $540 million private placement led by DRW and Liberty City Ventures to establish a treasury strategy focused on Canton Coin. The offering, which involves participation from several prominent investors, aims to support interoperability and settlement within the Canton Network. With this capital, Tharimmune plans to function as a Super Validator while developing applications for institutional use. The company emphasizes the transformative potential of their blockchain technology in reshaping financial infrastructure. The closing of the offering is expected around November 6, 2025, pending customary conditions.
Read more →CNTNTHARIMMUNE
Tharimmune, as reflected in its balance sheet for August 31, 2025, shows total assets of approximately $9.03 million and total liabilities of $2.15 million. The company's stockholders' equity stands at roughly $6.88 million, but it is overshadowed by a significant accumulated deficit exceeding $42 million. This financial structure may raise concerns about the company’s profitability and future financial health.
Read more →CNTNNancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors RED BANK, NJ / ACCESS Newswire /
Nancy Davis, a well-known philanthropist and advocate for multiple sclerosis and addiction treatment, has been appointed to Tharimmune's Board of Directors. With a personal history of MS, Davis founded Race to Erase MS and Cure Addiction Now, significantly contributing to medical research funding. Tharimmune aims to leverage her experience to enhance its development of critical therapies, including TH104 for opioid response in military and chemical incident contexts. Davis expressed her enthusiasm for joining Tharimmune, impressed by their commitment to transformative solutions in healthcare.
Read more →CNTNTharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants RED BANK, NJ / ACCESS Newswire /
Tharimmune, Inc. has announced the pricing of a registered direct public offering amounting to $1.74 million, which includes shares of common stock and pre-funded warrants. This offering, conducted under a previously filed Shelf Registration Statement, is expected to close on July 25, 2025, subject to customary conditions. The company intends to use the proceeds for working capital and general corporate purposes. President Street Global, LLC is acting as the exclusive placement agent for this offering.
Read more →CNTNTharimmune Announces $2.02 Million Private Placement to Advance Development Programs BRIDGEWATER, N.J. / ACCESSWIRE /
Tharimmune, Inc. has announced a private placement netting approximately $2.02 million to further its clinical development programs. The financing entails issuing shares and warrants, with the proceeds earmarked for advancing the TH104 program, which targets chronic pruritus related to primary biliary cholangitis. Led by Gravitas Capital and others, this financing reflects investor support for Tharimmune's innovative therapies in immunology and inflammation.
Read more →CNTNTharimmune Acquires Global License and Partners with Intract Pharma to Develop an Oral Formulation of Infliximab BRIDGEWATER, N.J. and LONDON / ACCESSWIRE /
Tharimmune, a clinical-stage biotechnology company, has entered into a global licensing agreement with Intract Pharma to develop an oral formulation of infliximab. This collaboration allows Tharimmune exclusive rights to use Intract's delivery platform, aiming to enhance patient compliance and treatment efficacy for chronic inflammatory diseases. The partnership is expected to broaden Tharimmune's therapeutic focus and accelerate the development of more accessible treatment options. Intract Pharma will receive upfront payments and potential future royalties based on product sales.
Read more →CNTNTharimmune Announces $2.08 Million Private Placement BRIDGEWATER, N.J. / ACCESSWIRE /
Tharimmune, Inc. has announced a private placement agreement to raise $2.08 million through the sale of 659,545 shares and warrants. The funding is intended to aid in the clinical development of TH104, a treatment for chronic pruritus in primary biliary cholangitis, as well as for general working capital. The offering is led by SDS Capital Group, with an expected closing date around June 21, 2024, subject to customary conditions.
Read more →CNTNTharimmune Announces 1-for-15 Reverse Stock Split BRIDGEWATER, N.J.
Tharimmune, Inc. has announced a 1-for-15 reverse stock split aimed at maintaining compliance with Nasdaq's minimum bid price requirement. This corporate action will occur after trading on May 24, 2024, and will result in approximately 785,978 shares outstanding post-split. Despite this move, the company cannot guarantee that the split will ensure compliance with Nasdaq regulations. Tharimmune continues to develop therapeutic candidates for rare diseases, including a focus on immuno-oncology pipelines.
Read more →CNTNTharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic p
Tharimmune has announced positive results from Phase 1 clinical trials for TH104, its lead therapeutic candidate intended for chronic pruritus associated with primary biliary cholangitis (PBC). The trials achieved their primary objective of predictable pharmacokinetic profiling, showing favorable safety and tolerability. The company plans to engage the FDA regarding the Phase 2 trial design, with topline data expected in 2024. TH104 is designed to improve conditions for patients suffering from debilitating itching, where current treatment options are limited.
Read more →CNTNTharimmune Announces 1-for-25 Reverse Stock Split BRIDGEWATER, N.J.
Tharimmune, Inc. has announced a 1-for-25 reverse stock split of its shares, aimed at ensuring compliance with Nasdaq's minimum bid price requirement. This decision was approved by stockholders at the Annual Meeting held on October 23, 2023, and will take effect on November 20, 2023. Post-split, the company anticipates having approximately 700,474 shares of common stock outstanding. However, the success of this strategy in achieving compliance remains uncertain.
Read more →CNTNTharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis Expects completion and topline data of a Phase 2 clinical trial in chronic pruritis over approximately 12
Tharimmune, Inc. has entered into an exclusive worldwide licensing agreement with Avior Inc. to develop TH104, a clinical-stage asset aimed at treating chronic pruritis associated with primary biliary cholangitis (PBC). The innovative product uses a proprietary transdermal buccal film for delivery, potentially providing effective treatment by bypassing the liver's first-pass metabolism. Tharimmune plans to conduct Phase 1 and Phase 2 trials over the next 12 months, with the first approval targeting the orphan disease category. This agreement marks a significant step in Tharimmune's transition towards a clinical development-focused business model.
Read more →CNTNHillstream BioPharma progressing towards acquiring clinical stage asset and announces corporate name change to Tharimmune, Inc. Expects to launch and complete a Phase 1 trial in Q4 2023 Tharimmune to begin trading under
Hillstream BioPharma, now renamed Tharimmune, Inc., is focusing on acquiring a clinical stage asset, TH104, aimed at treating uncontrollable itching related to primary biliary cholangitis. The company anticipates launching a Phase 1 trial by the end of 2023, building on previous successful trials that demonstrated the asset's bioavailability. The new corporate name emphasizes a commitment to developing patient-centric therapies. Trading under the ticker THAR will begin on September 25, 2023.
Read more →CNTNHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson Appointment to Enhance Board's Expertise Across Investments, Business Development and Capital Markets BRIDGEWATER, N.J.
Hillstream BioPharma has announced the appointment of Kelly Anderson to its Board of Directors as of May 9, 2023. Anderson, who possesses over 25 years of experience in public company finance and corporate governance, will enhance the board's expertise in investments and business development. The company aims to leverage her extensive background to further develop its pipeline of immuno-oncology targeted biologics and advance its clinical studies, particularly with HSB-1216, a candidate focusing on drug-resistant cancers. This strategic addition is expected to bolster the company’s ability to meet its growth objectives in the competitive biopharma landscape.
Read more →CNTNHillstream BioPharma Announces Proposed Public Offering BRIDGEWATER, N.J.
Hillstream BioPharma has announced its intention to conduct a public offering of its common stock and/or pre-funded warrants. The funds raised will be used to advance the development of its therapeutic candidates, including HSB-1216, which targets drug-resistant cancers. The extent of the offering and its terms are subject to market conditions. The company plans to initiate clinical studies in the latter part of 2023, while also highlighting potential risks associated with its drug development process.
Read more →Competitive Position
How CNTN ranks across every disease it competes inCompetitive Position is a premium feature
See how CNTN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial